Wolfe Research upgraded Inspire Medical (INSP) to Outperform from Peer Perform with an $180 price target The firm says the company’s “surprise” reimbursement increase adds conviction in the bull case for the shares. Wolfe’s price target represents 5-times Inspire’s estimated 2026 revenue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP: